Tasquinimod (BioDeep_00000184156)

   

human metabolite blood metabolite


代谢物信息卡片


4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-1,2-dihydroquinoline-3-carboxamide

化学式: C20H17F3N2O4 (406.1140358)
中文名称: 他喹莫德
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
InChI: InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3

描述信息

C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

同义名列表

3 个代谢物同义名

4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-1,2-dihydroquinoline-3-carboxamide; 4-Hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-((4-trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide; Tasquinimod



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, Nathalie Germann, Jean-Christophe Pouget, Ruth Plummer, Ignace Vergote, Fiona Thistlethwaite, Georg A Bjarnason, Robert Jones, Helen Mackay, Julien Edeline, Laetitia Fartoux, Hal Hirte, Amit Oza. A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted oncology. 2017 10; 12(5):655-661. doi: 10.1007/s11523-017-0525-2. [PMID: 28798986]
  • Selma Mahiout, Jere Lindén, Javier Esteban, Ismael Sánchez-Pérez, Satu Sankari, Lars Pettersson, Helen Håkansson, Raimo Pohjanvirta. Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats. Toxicology and applied pharmacology. 2017 07; 326(?):54-65. doi: 10.1016/j.taap.2017.04.020. [PMID: 28433708]
  • Lisa U Magnusson, Malin Hagberg Thulin, Pascale Plas, Anders Olsson, Jan-Erik Damber, Karin Welén. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment. The Prostate. 2016 Mar; 76(4):383-93. doi: 10.1002/pros.23133. [PMID: 26660725]
  • Leif D Svensson, Carl-Johan Sennbro, Camilla Svanström, Gunnar P Hansson. Applying dried blood spot sampling with LCMS quantification in the clinical development phase of tasquinimod. Bioanalysis. 2015; 7(2):179-91. doi: 10.4155/bio.14.259. [PMID: 25587835]
  • John T Isaacs, Susan L Dalrymple, D Marc Rosen, Hans Hammers, Anders Olsson, Tomas Leanderson. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep; 5(18):8093-106. doi: 10.18632/oncotarget.2378. [PMID: 25193858]
  • Nico C van de Merbel, Peter Walland, Mikael Tiensuu, Carl J Sennbro. Quantitative determination of the anti-tumor agent tasquinimod in human urine by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2014 Jun; 961(?):42-8. doi: 10.1016/j.jchromb.2014.05.007. [PMID: 24858264]
  • Marijo Bilusic, Yu-Ning Wong. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian journal of andrology. 2014 May; 16(3):372-7. doi: 10.4103/1008-682x.125903. [PMID: 24759579]
  • Karin Jennbacken, Karin Welén, Anders Olsson, Bengt Axelsson, Marie Törngren, Jan-Erik Damber, Tomas Leanderson. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). The Prostate. 2012 Jun; 72(8):913-24. doi: 10.1002/pros.21495. [PMID: 22287276]
  • G P Hansson, M Olin, C Svanström, L D Svensson, C J Sennbro. Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2011 Nov; 879(30):3401-6. doi: 10.1016/j.jchromb.2011.09.013. [PMID: 21963277]
  • Clara Hwang, Elisabeth I Heath. Angiogenesis inhibitors in the treatment of prostate cancer. Journal of hematology & oncology. 2010 Aug; 3(?):26. doi: 10.1186/1756-8722-3-26. [PMID: 20678204]
  • Susan L Dalrymple, Robin E Becker, John T Isaacs. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. The Prostate. 2007 May; 67(7):790-7. doi: 10.1002/pros.20573. [PMID: 17373719]